Search Result

Results for "

plasminogen activator inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PAI-1 (40) Akt (1) Amino Acid Derivatives (1) AMPK (3) Amyloid-β (1) Androgen Receptor (1) Annexin A (2) Antibiotic (1) Apoptosis (17) Autophagy (1) Biochemical Assay Reagents (1) COX (1) Drug Intermediate (1) Drug Isomer (1) ERK (3) Factor Xa (2) HSP (1) IGF-1R (3) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (5) JNK (3) Liposome (1) Mitophagy (3) MMP (8) Potassium Channel (2) Progesterone Receptor (1) PROTAC Linkers (1) Proteasome (1) Reactive Oxygen Species (ROS) (1) Reference Standards (8) Ser/Thr Protease (16) Sodium Channel (9) TGF-beta/Smad (1) Thrombin (2) Transmembrane Glycoprotein (1) TRP Channel (8)
By Research Areas:	Cancer (29) Cardiovascular Disease (31) Endocrinology (1) Infection (3) Inflammation/Immunology (15) Metabolic Disease (11) Neurological Disease (11)

By Targets:

PAI-1 (40)

Akt (1)

Amino Acid Derivatives (1)

AMPK (3)

Amyloid-β (1)

Androgen Receptor (1)

Annexin A (2)

Antibiotic (1)

Apoptosis (17)

Autophagy (1)

Biochemical Assay Reagents (1)

COX (1)

Drug Intermediate (1)

Drug Isomer (1)

ERK (3)

Factor Xa (2)

HSP (1)

IGF-1R (3)

Integrin (1)

Interleukin Related (1)

Isotope-Labeled Compounds (5)

JNK (3)

Liposome (1)

Mitophagy (3)

MMP (8)

Potassium Channel (2)

Progesterone Receptor (1)

PROTAC Linkers (1)

Proteasome (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (8)

Ser/Thr Protease (16)

Sodium Channel (9)

TGF-beta/Smad (1)

Thrombin (2)

Transmembrane Glycoprotein (1)

TRP Channel (8)

By Research Areas:

Cancer (29)

Cardiovascular Disease (31)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (15)

Metabolic Disease (11)

Neurological Disease (11)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Plasminogen/Plasmin PAI-1

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-B0099

Edaravone 40+ Cited Publications MCI-186	MMP Apoptosis	Neurological Disease
Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.

HY-B0285

Amiloride Maximum Cited Publications 62 Publications Verification MK-870	Sodium Channel TRP Channel Apoptosis	Cardiovascular Disease Metabolic Disease
Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride is a blocker of polycystin-2 (PC2; TRPP2 ) channel.

HY-15253

Tiplaxtinin 10+ Cited Publications PAI-039; Tiplasinin	PAI-1 Apoptosis	Metabolic Disease Cancer
Tiplaxtinin is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC₅₀ of 2.7 μM .

HY-B0285A

Amiloride hydrochloride Maximum Cited Publications 62 Publications Verification MK-870 hydrochloride	Sodium Channel TRP Channel Apoptosis	Cardiovascular Disease Metabolic Disease
Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride hydrochloride is a blocker of polycystin-2 (PC2; TRPP2 ) channel.

HY-B0149

Tranexamic acid 1 Publications Verification cyclocapron	IGF-1R AMPK MMP Mitophagy PROTAC Linkers	Cardiovascular Disease Neurological Disease Cancer
Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis. Tranexamic acid is a PROTAC linker. Tranexamic acid is used to synthesize PROTACs (e.g. LZ-07 (HY-172590)) .

HY-101761

TM5441 5+ Cited Publications	PAI-1 Apoptosis	Cardiovascular Disease Cancer
TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1), has IC₅₀ values between 13.9 and 51.1 μM and induces intrinsic apoptosis in several human cancer cell lines. TM5441 attenuates Nω-nitro-l-arginine methyl ester-induced cardiac hypertension and vascular senescence .

HY-B0111

Drospirenone 1 Publications Verification Dihydrospirorenone	Progesterone Receptor Androgen Receptor	Endocrinology Cancer
Drospirenone (Dihydrospirorenone) is an orally active fourth-generation progestin that interacts with the progesterone receptor (PR) and androgen receptor (AR). Drospirenone significantly decreases both plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) via the AR. Drospirenone can produce DNA damage in bone marrow cells of female mice. .

HY-P2333

LCKLSL 5+ Cited Publications	Annexin A	Cardiovascular Disease
LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the *binding of tissue plasminogen* activator (tPA) to AnxA2*. LCKLSL also inhibits* the generation of plasmin and has anti-angiogenic roles .

HY-111056

UK122 TFA 1 Publications Verification	Ser/Thr Protease	Cancer
UK122 is a potent and selective *urokinase-type plasminogen* activator (uPA)** inhibitor with an IC₅₀ of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC₅₀>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion .

HY-16511

Upamostat 1 Publications Verification WX-671	PAI-1 Ser/Thr Protease	Infection Cancer
Upamostat (WX-671), a prodrug of WX-UK1, is an orally active serine protease inhibitor. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, blocking the plasminogen activation process mediated by it, thereby suppressing the invasion, migration and metastasis of tumor cells. Upamostat can be used in the research of metastatic breast cancer and locally advanced pancreatic cancer .

HY-B0285B

Amiloride hydrochloride dihydrate Maximum Cited Publications 62 Publications Verification MK-870 hydrochloride dihydrate	Sodium Channel Apoptosis TRP Channel	Cardiovascular Disease Metabolic Disease
Amiloride hydrochloride dihydrate (MK-870 hydrochloride dihydrate) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride hydrochloride dihydrate is a blocker of polycystin-2 (PC2; TRPP2 ) channel.

HY-P2333A

LCKLSL hydrochloride 5+ Cited Publications	Annexin A	Cardiovascular Disease
LCKLSL hydrochloride is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL hydrochloride potently inhibits the *binding of tissue plasminogen* activator (tPA) to AnxA2*. LCKLSL hydrochloride also inhibits* the generation of plasmin and has anti-angiogenic roles .

HY-N1504

Loureirin B 4 Publications Verification	PAI-1 Potassium Channel ERK JNK	Metabolic Disease
Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC₅₀ of 26.10 μM; Loureirin B also inhibits K_ATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.

HY-B0099R

Edaravone (Standard) MCI-186 (Standard)	Reference Standards MMP Apoptosis	Neurological Disease
Edaravone (Standard) is the analytical standard of Edaravone. This product is intended for research and analytical applications. Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.

HY-W018723

4-Aminobenzamidine dihydrochloride 1 Publications Verification p-Aminobenzamidine dihydrochloride	Ser/Thr Protease PAI-1	Cardiovascular Disease Cancer
4-Aminobenzamidine (p-Aminobenzamidine) dihydrochloride is a strong trypsin inhibitor. 4-Aminobenzamidine dihydrochloride acts as an orally active *urokinase type plasminogen* activator (uPA)** inhibitor (K_i=82 μM). 4-Aminobenzamidine dihydrochloride can be used for cardiovascular diseases and anti-tumor study .

HY-101214

UK-371804	PAI-1	Inflammation/Immunology
UK-371804 is a urokinase-type plasminogen activator (uPA) inhibitor with a K_i of 10 nM.

HY-100415

UKI-1 WX-UK1; UKI-1C	PAI-1 Ser/Thr Protease	Cancer
UKI-1 (WX-UK1) is a potent *urokinase-type plasminogen* activator (uPA)** inhibitor with a K_i of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells .

HY-122098

Diaplasinin PAI-749	PAI-1	Cardiovascular Disease
Diaplasinin (PAI-749) is a plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC₅₀ of 295 nM. Diaplasinin has antithrombotic efficacy .

HY-14759

Aleplasinin PAZ-417	PAI-1 Amyloid-β	Neurological Disease
Aleplastinin (PAZ-417) is an orally active, blood-brain barrier permeable, selective SERPINE1 (PAI-1) inhibitor (IC₅₀=655 nM). Aleplastinin activates the *tissue type plasminogen* activator (tPA)/fibrinolysis** cascade by inhibiting PAI-1, thereby promoting the degradation of amyloid-β (Aβ) oligomers and monomers. Aleplastinin can significantly reduce plasma and brain Aβ levels, improve memory impairment, and reverse cognitive impairment. Aleplastinin can be used for research on Alzheimer's disease .

HY-P990552A

huATN-658	PAI-1 Integrin	Cancer
huATN-658 is an inhibitor that specifically targets the DIII domain of human urokinase plasminogen activator receptor (uPAR). huATN-658 neutralizes uPAR function by blocking the interaction between uPAR and integrins, without interfering with the binding of uPA or vitronectin to uPAR. huATN-658 inhibits the proliferation and invasion of breast cancer cells, slows the growth of primary breast tumors, reduces breast cancer-induced bone lesions and decreases osteoclast activity. huATN-658 also alters the gene expression of the TGF-β receptor complex signaling pathway. huATN-658 exerts synergistic anticancer effects when combined with Zoledronic Acid (HY-13777), and does not cause physiological or behavioral abnormalities in immunodeficient mice. huATN-658 can be used in research related to breast cancer, metastatic breast cancer and breast cancer-induced bone disease .

HY-122311

Orniplabin SMTP-7	Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology
Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin shows potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits ROS .

HY-P1615

Cenupatide	Transmembrane Glycoprotein	Cancer
Cenupatide (UPARANT) is a *Urokinase-type plasminogen* activator receptor (uPAR)** inhibitor. Cenupatide has anti-angiogenic and anti-inflammatory efficacy .

HY-N0518

Toddalolactone 1 Publications Verification	PAI-1	Cardiovascular Disease
Toddalolactone, a main component of Toddalia asiatica, inhibits the activity of recombinant *human plasminogen* activator inhibitor-1 (PAI-1)**, with an IC₅₀ value of 37.31 μM .

HY-122714

SK-216	PAI-1	Cancer
SK-216 is a plasminogen activator inhibitor-1 (PAI-1) inhibitor that acts as an anti-metastatic agent for human osteosarcoma and inhibits lung metastasis of human osteosarcoma .

HY-N2082

Isorhamnetin 3-O-galactoside 1 Publications Verification Cacticin	Thrombin COX ERK JNK Factor Xa	Cardiovascular Disease Inflammation/Immunology
Isorhamnetin 3-O-galactoside (Cacticin) is a flavonoid glycoside that can be isolated from Oenanthe javanica, with antithrombotic and profibrinolytic activities. Isorhamnetin 3-O-galactoside inhibits the activities of thrombin and factor Xa (FXa) and reduces thrombin-catalyzed fibrin polymerization maximum rate. Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion, decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, and inhibits FXa production and FVa/FXa-mediated thrombin generation. Isorhamnetin 3-O-galactoside exerts protective effects against Carbon tetrachloride (CCl4) (HY-Y0298)-induced hepatic injury in mice. Isorhamnetin 3-O-galactoside can be used for the study of liver injury-related diseases and thrombotic vascular diseases .

HY-165084

L-a-Phosphatidylserine sodium Soy PS sodium	Liposome PAI-1	Cardiovascular Disease Inflammation/Immunology
L-α-Phosphatidylserine sodium (Soy PS sodium) is a negatively charged phospholipid that acts as an allosteric activator to activate latent plasminogen activator inhibitor-1 (PAI-1). L-α-Phosphatidylserine does not directly alter the catalytic activity of t-PA, but regulates fibrinolytic activity solely by inducing conformational remodeling of PAI-1. L-α-Phosphatidylserine sodium is an antigen targeting phosphatidylserine (PS) and can induce the production of polyclonal antibodies. L-α-Phosphatidylserine is mainly used in studies related to immunology, fibrinolytic system and coagulation homeostasis .

HY-114330A

ZK824859 hydrochloride	PAI-1 Ser/Thr Protease	Inflammation/Immunology
ZK824859 hydrochloride is an oral available and selective urokinase plasminogen activator (uPA) inhibitor with IC₅₀s of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively .

HY-W008753

Z-L-Val-OH N-Cbz-L-valine	Biochemical Assay Reagents Drug Intermediate Amino Acid Derivatives	Infection
Z-L-Val-OH (N-Cbz-L-valine) is an amino acid derivative and key intermediate in organic synthesis. Z-L-Val-OH can be used in the synthesis of anti-cytomegalovirus compounds and peptide inhibitors of human spleen plasminogen activator (SFP) and human leukocyte elastase-like protease (ELP) .

HY-B0285AR

Amiloride hydrochloride (Standard) 15+ Cited Publications MK-870 hydrochloride (Standard)	Reference Standards Sodium Channel TRP Channel Apoptosis	Cardiovascular Disease Metabolic Disease
Amiloride (hydrochloride) (Standard) is the analytical standard of Amiloride (hydrochloride). This product is intended for research and analytical applications. Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride hydrochloride is a blocker of polycystin-2 (PC2; TRPP2 ) channel.

HY-117724

AZ3976	PAI-1	Cardiovascular Disease
AZ3976 is a potent plasminogen activator inhibitor type 1 (PAI-1) inhibitor with an IC₅₀ value of 26 μM in an enzymatic chromogenic assay. AZ3976 is active with an IC₅₀ of 16 μM in a plasma clot lysis assay. AZ3976 does not bind to active PAI-1 but bound reversibly to latent PAI-1. AZ3976 inhibits PAI-1 by enhancing the latency transition of active PAI-1. AZ3976 displays profibrinolytic activities in a human plasma clot lysis assay .

HY-126361A

ZK824190 hydrochloride 1 Publications Verification	Ser/Thr Protease PAI-1	Inflammation/Immunology
ZK824190 hydrochloride is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC₅₀s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively .

HY-126361

ZK824190	Ser/Thr Protease PAI-1	Inflammation/Immunology
ZK824190 is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC₅₀s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively .

HY-116868

Anecortave acetate Anecortave	PAI-1	Cardiovascular Disease
Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases .

HY-173272

BT-114143	PAI-1	Cardiovascular Disease
BT-114143 is a *plasminogen* activation inhibitor, with an IC₅₀ of 8.42 μM. BT-114143 can be used in the research of hemorrhagic diseases caused by hyperfibrinolysis, such as traumatic bleeding, severe menstrual bleeding, postpartum hemorrhage, and complications of hemophilia .

HY-B0149R

Tranexamic acid (Standard) cyclocapron (Standard)	Reference Standards IGF-1R AMPK MMP Mitophagy	Cardiovascular Disease Neurological Disease Cancer
Tranexamic acid (Standard) is the analytical standard of Tranexamic acid. This product is intended for research and analytical applications. Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis .

HY-100939

4-Chlorophenylguanidine hydrochloride	Sodium Channel	Neurological Disease
4-Chlorophenylguanidine hydrochloride is an urokinase-type plasminogen activator inhibitor. 4-Chlorophenylguanidine hydrochloride is a potent ASIC3 positive allosteric modulator and reverses the effects of ASIC3 desensitization. 4-Chlorophenylguanidine hydrochloride influences ASIC3 activity through directly activating the channel and increasing proton sensitivity. 4-Chlorophenylguanidine hydrochloride offers a chemical backbone for the design of new ASIC3 ligands to study ASIC3 in vivo .

HY-N10227

Geodin	PAI-1 Antibiotic	Infection Inflammation/Immunology
Geodin, a fungal metabolite, shows antibacterial activity. Geodin also is an inhibitor of plasminogen activator inhibitor- 1 (PAI-1) .

HY-P10877

Bicyclic UK18	PAI-1	Cancer
Bicyclic UK18 is a competitive inhibitor for human urokinase-type plasminogen activator (uPA) with a K_i of 53 nM .

HY-B0285R

Amiloride (Standard) MK-870 (Standard)	Sodium Channel TRP Channel Apoptosis Reference Standards	Cardiovascular Disease Metabolic Disease
Amiloride (Standard) is the analytical standard of Amiloride. This product is intended for research and analytical applications. Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride is a blocker of polycystin-2 (PC2; TRPP2 ) channel.

HY-P11413

PAI-1	Ser/Thr Protease	Cardiovascular Disease
PAI-1 is a plasminogen activator inhibitor. PAI-1 is a member of the Ser Protease inhibitor superfamily with antiprotease activity. PAI-1 is the main physiological inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators (PAs) .

HY-106508

Fendosal HP 129; P 71-0129	PAI-1	Inflammation/Immunology
Fendosal (HP 129) is an orally active, potent non-steroidal anti-inflammatory agent. Fendosal (HP 129) is also an inhibitor of Plasminogen activator inhibitor-1 (PAI-1) .

HY-114330

ZK824859	PAI-1 Ser/Thr Protease	Inflammation/Immunology
ZK824859 is an oral available and selective urokinase plasminogen activator (uPA) inhibitor with IC₅₀s of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively .

HY-B0099S

Edaravone-d5 MCI-186-d₅	Isotope-Labeled Compounds MMP Apoptosis	Neurological Disease
Edaravone-d₅ is a deuterium labeled Edaravone. Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator .

HY-B0285AS

Amiloride-15N3 hydrochloride MK-870-15N3 hydrochloride	Apoptosis TRP Channel Sodium Channel	Metabolic Disease
Amiloride- ¹⁵N₃ (hydrochloride) is the ¹⁵N labeled Amiloride hydrochloride . Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride hydrochloride is a blocker of polycystin-2 (PC2;TRPP2 ) channel.

HY-101761A

TM5441 sodium	PAI-1 Apoptosis	Cardiovascular Disease Cancer
TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1), has IC₅₀ values between 13.9 and 51.1 μM. TM5441 induces intrinsic apoptosis in several human cancer cell lines. TM5441 attenuates Nω-nitro-l-arginine methyl ester-induced cardiac hypertension and vascular senescence .

HY-111056A

UK122 hydrochloride 1 Publications Verification	Ser/Thr Protease	Cancer
UK122 hydrochloride is a potent and selective *urokinase-type plasminogen* activator (uPA)** inhibitor with an IC₅₀ of 0.2 μM. UK122 hydrochloride shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC₅₀s > 100 μM). UK122 hydrochloride, a 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion .

HY-B0149S2

Tranexamic acid-13C6 Cyclocapron-¹³C₆	Isotope-Labeled Compounds MMP Mitophagy IGF-1R AMPK	Cardiovascular Disease Neurological Disease Cancer
Tranexamic acid- ¹³C₆ (Cyclocapron- ¹³C₆) is ¹³C labeled Tranexamic acid. Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis .

HY-101214A

UK-371804 hydrochloride	PAI-1	Others
UK-371804 hydrochloride (compound 24) is a *urokinase-type plasminogen* activator (uPA)** inhibitor with a K_i of 10 nM .

HY-N1533

28-O-β-D-Glucopyranosyl pomolic acid	PAI-1	Inflammation/Immunology
28-O-β-D-Glucopyranosyl pomolic acid is a urokinase plasminogen activator inhibitor with IC₅₀ at 37.82 μM .

HY-137495

GGACK	PAI-1 Ser/Thr Protease	Cancer
GGACK (H-Glu-Gly-Arg-CMK) is an irreversible substrate-like *serine protease urokinase-type plasminogen* activator (uPA)** inhibitor .

Art. -Nr.	Produktname	Target	Research Area

HY-P2333

LCKLSL 5+ Cited Publications	Annexin A	Cardiovascular Disease
LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the *binding of tissue plasminogen* activator (tPA) to AnxA2*. LCKLSL also inhibits* the generation of plasmin and has anti-angiogenic roles .

HY-P2333A

LCKLSL hydrochloride 5+ Cited Publications	Annexin A	Cardiovascular Disease
LCKLSL hydrochloride is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL hydrochloride potently inhibits the *binding of tissue plasminogen* activator (tPA) to AnxA2*. LCKLSL hydrochloride also inhibits* the generation of plasmin and has anti-angiogenic roles .

HY-P1615

Cenupatide	Transmembrane Glycoprotein	Cancer
Cenupatide (UPARANT) is a *Urokinase-type plasminogen* activator receptor (uPAR)** inhibitor. Cenupatide has anti-angiogenic and anti-inflammatory efficacy .

HY-P10877

Bicyclic UK18	PAI-1	Cancer
Bicyclic UK18 is a competitive inhibitor for human urokinase-type plasminogen activator (uPA) with a K_i of 53 nM .

HY-P11413

PAI-1	Ser/Thr Protease	Cardiovascular Disease
PAI-1 is a plasminogen activator inhibitor. PAI-1 is a member of the Ser Protease inhibitor superfamily with antiprotease activity. PAI-1 is the main physiological inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators (PAs) .

HY-137495

GGACK	PAI-1 Ser/Thr Protease	Cancer
GGACK (H-Glu-Gly-Arg-CMK) is an irreversible substrate-like *serine protease urokinase-type plasminogen* activator (uPA)** inhibitor .

HY-137495A

GGACK hydrochloride	PAI-1 Ser/Thr Protease	Cancer
GGACK (H-Glu-Gly-Arg-CMK) hydrochloride is an irreversible substrate-like *serine protease urokinase-type plasminogen* activator (uPA)** inhibitor .

HY-P10878

UK140	PAI-1	Cancer
UK140 is the inhibitor for urokinase-type plasminogen activator (uPA) with K_i of 0.20 µM and 2.79 µM for huPA anf muPA. UK140 can be used in metastasis-related research .

Art. -Nr.	Produktname	Target	Research Area	Image

HY-P990552A

huATN-658	PAI-1 Integrin	Cancer
huATN-658 is an inhibitor that specifically targets the DIII domain of human urokinase plasminogen activator receptor (uPAR). huATN-658 neutralizes uPAR function by blocking the interaction between uPAR and integrins, without interfering with the binding of uPA or vitronectin to uPAR. huATN-658 inhibits the proliferation and invasion of breast cancer cells, slows the growth of primary breast tumors, reduces breast cancer-induced bone lesions and decreases osteoclast activity. huATN-658 also alters the gene expression of the TGF-β receptor complex signaling pathway. huATN-658 exerts synergistic anticancer effects when combined with Zoledronic Acid (HY-13777), and does not cause physiological or behavioral abnormalities in immunodeficient mice. huATN-658 can be used in research related to breast cancer, metastatic breast cancer and breast cancer-induced bone disease .

HY-P990239

Anti-Human/Mouse GRP78 Antibody (N88)	HSP Akt Interleukin Related	Inflammation/Immunology Cancer
Anti-Human/Mouse GRP78 Antibody (N88) is an anti-human/mouse GRP78 IgG1 monoclonal antibody. Anti-Human/Mouse GRP78 Antibody (N88) can activate the Akt signaling pathway. Anti-Human/Mouse GRP78 Antibody (N88) can inhibit the expression of inflammatory factors and plasminogen activator inhibitors induced by TLR agonists. Anti-Human/Mouse GRP78 Antibody (N88) can be used for research on inflammation conditions. Anti-Human/Mouse GRP78 Antibody (N88) can be used for immunoprecipitation .

HY-P992313

AS3288802	PAI-1	Cardiovascular Disease
AS3288802, a highly selective active **plasminogen activator inhibitor-1 (PAI-1*) antibody, is a PAI-1 inhibitor* with a human IC₅₀ and EC₅₀ values of 4.2 ng/mL. AS3288802 can be used for the research of thrombosis and fibrosis-related diseases .

HY-P992410

MEDI-579	PAI-1 TGF-beta/Smad	Inflammation/Immunology
MEDI-579 is a fully human monoclonal antibody against PAI-1, with a K_D value of 6 pM for human PAI-1 and 105 pM for rat PAI-1. MEDI-579 restores renal plasmin activity and inhibits PAI-1-mediated intracellular signal transduction. MEDI-579 reduces albuminuria, glomerulosclerosis severity, TGF-β1 expression level, and phosphorylated Smad2 level induced in diabetic mice. MEDI-579 decreases the levels of active PAI-1 in plasma and kidneys, and increases plasma plasmin level in a mouse model of lupus nephritis. MEDI-579 can be used in research related to diabetic nephropathy and lupus nephritis. The recommended isotype control is human IgG1 kappa (HY-P99001) .

Art. -Nr.	Produktname	Category	Target	Chemical Structure

HY-N1504

Loureirin B 4 Publications Verification	Dracaena cochinchinensis (Lour.) S. C. Chen Monophenols Flavonoids Classification of Application Fields Phenols Metabolic Disease Agavaceae Plants Dihydrochalcones Disease Research Fields Source Classification	PAI-1 Potassium Channel ERK JNK
Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC₅₀ of 26.10 μM; Loureirin B also inhibits K_ATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.

HY-N0518

Toddalolactone 1 Publications Verification	Toddalia asiatica (L.) Lam. Cardiovascular Disease Classification of Application Fields Rutaceae Coumarins Phenylpropanoids Plants Disease Research Fields Source Classification	PAI-1
Toddalolactone, a main component of Toddalia asiatica, inhibits the activity of recombinant *human plasminogen* activator inhibitor-1 (PAI-1)**, with an IC₅₀ value of 37.31 μM .

HY-N2082

Isorhamnetin 3-O-galactoside 1 Publications Verification Cacticin	Cardiovascular Disease Flavonols Flavonoids Typhaceae Classification of Application Fields Typha angustifolia L. Phenols Polyphenols Plants Disease Research Fields Source Classification	Thrombin COX ERK JNK Factor Xa
Isorhamnetin 3-O-galactoside (Cacticin) is a flavonoid glycoside that can be isolated from Oenanthe javanica, with antithrombotic and profibrinolytic activities. Isorhamnetin 3-O-galactoside inhibits the activities of thrombin and factor Xa (FXa) and reduces thrombin-catalyzed fibrin polymerization maximum rate. Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion, decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, and inhibits FXa production and FVa/FXa-mediated thrombin generation. Isorhamnetin 3-O-galactoside exerts protective effects against Carbon tetrachloride (CCl4) (HY-Y0298)-induced hepatic injury in mice. Isorhamnetin 3-O-galactoside can be used for the study of liver injury-related diseases and thrombotic vascular diseases .

HY-N10227

Geodin	Human Gut Microbiota Metabolites Monophenols Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Phenols Endogenous metabolite Disease Research Fields Inflammation/Immunology Source Classification	PAI-1 Antibiotic
Geodin, a fungal metabolite, shows antibacterial activity. Geodin also is an inhibitor of plasminogen activator inhibitor- 1 (PAI-1) .

HY-N1533

28-O-β-D-Glucopyranosyl pomolic acid	Triterpenes Classification of Application Fields Terpenoids Rosaceae Potentilla anserina Linn. Plants Inflammation/Immunology Disease Research Fields Source Classification	PAI-1
28-O-β-D-Glucopyranosyl pomolic acid is a urokinase plasminogen activator inhibitor with IC₅₀ at 37.82 μM .

HY-N0518R

Toddalolactone (Standard)	Toddalia asiatica (L.) Lam. Structural Classification Rutaceae Coumarins Phenylpropanoids Plants Source Classification	Reference Standards PAI-1
Toddalolactone (Standard) is the analytical standard of Toddalolactone. This product is intended for research and analytical applications. Toddalolactone, a main component of Toddalia asiatica, inhibits the activity of recombinant human plasminogen activator inhibitor-1 (PAI-1), with an IC50 value of 37.31 μM .

HY-N1504R

Loureirin B (Standard)	Dracaena cochinchinensis (Lour.) S. C. Chen Structural Classification Monophenols Flavonoids Phenols Agavaceae Plants Dihydrochalcones Source Classification	Reference Standards PAI-1 Potassium Channel ERK JNK
Loureirin B (Standard) is the analytical standard of Loureirin B. This product is intended for research and analytical applications. Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC₅₀ of 26.10 μM; Loureirin B also inhibits KATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.

Species:	Human (6) Rat (2) Mouse (2)
Tag:	His (7) Tag Free (2) Fc (1)
Source:	HEK293 (6) Sf9 insect cells (1) E. coli (3)

Art. -Nr.	Compare	Produktname	Species	Source	Image

HY-P71921

	Serpin B2 Protein, Human HsT1201; Monocyte Arg serpin ; Monocyte Arg-serpin; Monocyte Arginine-serpin; Monocyte-derived plasminogen activator inhibitor; PAI; PAI-2; PAI2 ; PAI2_HUMAN; Placental plasminogen activator inhibitor; PLANH2 ; plasminogen activator inhibitor 2; plasminogen activator inhibitor; type 2; plasminogen activator inhibitor; type II arginine-serpin; ; serine or cysteine; proteinase inhibitor; clade B ovalbumin; ; member 2; Serpin B2; serpin peptidase inhibitor; clade B ovalbumin; ; member 2; Serpinb2; Urokinase inhibitor	Human	E. coli
	Serpin B2 inhibits urokinase-type plasminogen activator and contributes to fibrinolytic regulation. Monocyte-derived plasminogen activator inhibitor 2 (PAI-2) differs from endothelial cell-derived PAI-1, highlighting different cellular origins. Serpin B2 Protein, Human is the recombinant human-derived Serpin B2 protein, expressed by E. coli , with tag free. The total length of Serpin B2 Protein, Human is 415 a.a., with molecular weight of ~46.6 kDa.

HY-P705552

	Serpin B2 Protein, Human (HEK293, His) HsT1201; Monocyte Arg serpin ; Monocyte Arg-serpin; Monocyte Arginine-serpin; Monocyte-derived plasminogen activator inhibitor; PAI; PAI-2; PAI2 ; PAI2_HUMAN; Placental plasminogen activator inhibitor; PLANH2 ; plasminogen activator inhibitor 2; plasminogen activator inhibitor; type 2; plasminogen activator inhibitor; type II arginine-serpin; serine or cysteine; proteinase inhibitor; clade B ovalbumin; member 2; Serpin B2; serpin peptidase inhibitor; clade B ovalbumin; member 2; Serpinb2; Urokinase inhibitor	Human	HEK293

HY-P71133

	Serpin E1 Protein, Mouse (HEK293, His) 1 Publications Verification plasminogen activator inhibitor 1; Endothelial plasminogen activator inhibitor; Serpin E1; Mr1; Pai1; Planh1;	Mouse	HEK293
	Serpin E1 protein is a serine protease inhibitor that regulates TMPRSS7 and is a major inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU).It can significantly downregulate fibrinolysis and control thrombus degradation.Serpin E1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Serpin E1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P71077

	Serpin E1 Protein, Human (HEK293, His) 2 Publications Verification plasminogen activator inhibitor 1; PAI; PAI-1; Endothelial plasminogen activator inhibitor; Serpin E1; SERPINE1; PAI1; PLANH1	Human	HEK293
	Serpin E1 is a serine protease inhibitor that regulates various cellular processes by inhibiting TMPRSS7, tissue-type plasminogen activator (PLAT), and urokinase-type plasminogen activator (PLAU). During fibrinolysis, it downregulates PLAT to control thrombus degradation and acts as a PLAU inhibitor to regulate cell adhesion. Serpin E1 Protein, Human (HEK293, His) is the recombinant human-derived Serpin E1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P73655

	Serpin E1 Protein, Rat (HEK293, His) plasminogen activator inhibitor 1; PAI-1; Serpin E1; Serpine1; Planh1	Rat	HEK293
	Serpin E1 Protein, Rat (HEK293, His) is one important member of the serine proteinase inhibitor E superfamily that plays a crucial role in the fibrinolytic system. The Serpin E1 protein is a single-chain glycoprotein composed of 379 amino acids. The active site of the protein is Arg346-Met347. SERPINE1 encodes plasminogen activator inhibitor type 1 (PAI-1), which serves as the primary inhibitor of urokinase plasminogen activator (uPA) and tissue-type plasminogen activator (tPA). The Serpin E1 protein can quickly inhibit the formation of plasmin. Serpin E1 can be transcribed through several signaling cascades, including pro-fibrogenic and pro-inflammatory pathways. Serpin E1 is a serine proteinase inhibitor, serves as an important regulator of extracellular matrix remodeling. Serpin E1 Protein, Rat (HEK293, His) is the recombinant rat-derived Serpin E1 protein, expressed by HEK293 , with C-His, C-10*His labeled tag.

HY-P73336

	Serpin E1 Protein, Rat (HEK293, Fc) plasminogen activator inhibitor 1; PAI-1; Serpin E1; Serpine1; Planh1	Rat	HEK293
	Serpin E1 is a serine protease inhibitor that regulates TMPRSS7 and inhibits tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU).It can significantly downregulate fibrinolysis and control thrombus degradation.Serpin E1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived Serpin E1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P72055

	Serpin A5 Protein, Mouse (sf9, His) Serpina5; Pci; Plasma serine protease inhibitor; plasminogen activator inhibitor 3; PAI-3; PAI3; Protein C inhibitor; PCI; Serpin A5	Mouse	Sf9 insect cells
	Serpin A5 protein is a heparin-dependent serine protease inhibitor that controls proteolytic activity in body fluids. It binds irreversibly to the serine activation site, inactivating serine proteases and regulating intravascular and extravascular proteolysis. Serpin A5 Protein, Mouse (sf9, His) is the recombinant mouse-derived Serpin A5 protein, expressed by sf9 insect cells , with N-10*His labeled tag.

HY-P70975

	Serpin A5 Protein, Human (HEK293, His) 2 Publications Verification Plasma Serine Protease inhibitor; Acrosomal Serine Protease inhibitor; plasminogen activator inhibitor 3; PAI-3; PAI3; Protein C inhibitor; PCI; Serpin A5; SERPINA5; PCI; PLANH3; PROCI	Human	HEK293
	Plasma serine protease inhibitor (SERPINA5) is a glycoproteins that inhibit serine proteases. SERPINA5 is involved in the regulation of intravascular and extravascular proteolytic activities, controls the sperm motility and fertilization and protect components of the genital tract. SERPINA5 also inhibits urinary-type plasminogen activator-dependent tumor cell invasion and metastasis. Serpin A5 Protein, Human (HEK293, His) is the recombinant human-derived Serpin A5 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P701528

	HLTF Protein, Human HLTF; Helicase-like transcription factor; DNA-binding protein/plasminogen activator inhibitor 1 regulator; HIP116; RING finger protein 80; RING-type E3 ubiquitin transferase HLTF; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 3; Sucrose nonfermenting protein 2-like 3	Human	E. coli
	HLTF protein has helicase and E3 ubiquitin ligase activities and has intrinsic ATP-dependent nucleosome remodeling ability. It is critical for the transcriptional regulation of specific promoters such as SERPINE1, HIV-1 and SV40. HLTF Protein, Human is the recombinant human-derived HLTF protein, expressed by E. coli , with tag free.

HY-P701529

	HLTF Protein, Human (His) HLTF; Helicase-like transcription factor; DNA-binding protein/plasminogen activator inhibitor 1 regulator; HIP116; RING finger protein 80; RING-type E3 ubiquitin transferase HLTF; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 3; Sucrose nonfermenting protein 2-like 3	Human	E. coli
	HLTF protein has helicase and E3 ubiquitin ligase activities and has intrinsic ATP-dependent nucleosome remodeling ability. It is critical for the transcriptional regulation of specific promoters such as SERPINE1, HIV-1 and SV40. HLTF Protein, Human (His) is the recombinant human-derived HLTF protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	Auf Lager - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / Auf Lager - + In den Warenkorb hinzufügen Angebot einholen

Art. -Nr.	Produktname	Chemical Structure

HY-B0099S

Edaravone-d5
Edaravone-d₅ is a deuterium labeled Edaravone. Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator .

HY-B0285AS

Amiloride-15N3 hydrochloride
Amiloride- ¹⁵N₃ (hydrochloride) is the ¹⁵N labeled Amiloride hydrochloride . Amiloride hydrochloride (MK-870 hydrochloride) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride hydrochloride is a blocker of polycystin-2 (PC2;TRPP2 ) channel.

HY-B0149S2

Tranexamic acid-13C6
Tranexamic acid- ¹³C₆ (Cyclocapron- ¹³C₆) is ¹³C labeled Tranexamic acid. Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis .

HY-B0285S

Amiloride-15N3
Amiloride- ¹⁵N₃ (MK-870- ¹⁵N₃) is ¹⁵N labeled Amiloride. Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC ) and urokinase-type plasminogen activator receptor (uTPA ). Amiloride is a blocker of polycystin-2 (PC2; TRPP2 ) channel.

HY-W801479S

Edaravone sulfate-d5
Edaravone sulfate-d₅ is the deuterium labeled Edaravone sulfate. Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.

HY-100415S1

UKI-1-d8 acetate
UKI-1-d₈ acetate (WX-UK1-d₈ acetate) is the deuterium labeled UKI-1 acetate. UKI-1 (WX-UK1) is a potent *urokinase-type plasminogen* activator (uPA)** inhibitor with a K_i of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells .

Host:	Rabbit (2)
Reactivity:	Human (2) Mouse (2)
Application:	WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (1) Recombinant (1)
Modification:	Unmodified (1)

Art. -Nr.	Compare	Produktname	Application	Reactivity	Image

HY-P81779

	PAI1 Antibody (YA1524) SERPINE1; PAI1; PLANH1; plasminogen activator inhibitor 1; PAI; PAI-1; Endothelial plasminogen activator inhibitor; Serpin E1	WB	Human, Mouse
	PAI1 Antibody (YA1524) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PAI1.

HY-P81779A

	PAI1 Antibody (YA1524)(PBS only) SERPINE1; PAI1; PLANH1; plasminogen activator inhibitor 1; PAI; PAI-1; Endothelial plasminogen activator inhibitor; Serpin E1	WB	Human, Mouse
	PAI1 Antibody (YA1524) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PAI1.